N-Acetylcysteine-Enhanced Contrast Provides Cardiorenal Protection

JACC: Cardiovascular Interventions

Volumn 2, Issue 3, 2009, Pages 215-221

  Meyer, Markus ^a   LeWinter, Martin M ^a   Bell, Stephen P ^a   Chen, Zengyi ^a   Selby, Donald E ^a   Singla, Dinender K ^a   Dauerman, Harold L ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

antioxidants; contrast medium; ischemia; reperfusion

Indexed keywords

ACETYLCYSTEINE; IOPAMIDOL; CONTRAST MEDIUM; CREATININE; SCAVENGER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HISTOPATHOLOGY; INTRACORONARY INFUSION; KIDNEY TUBULE NECROSIS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; SWINE; ANIMAL; APOPTOSIS; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; FEASIBILITY STUDY; HEART MUSCLE; KIDNEY; KIDNEY DISEASES; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACETYLCYSTEINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; APOPTOSIS; CONTRAST MEDIA; CREATININE; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; FREE RADICAL SCAVENGERS; IOPAMIDOL; KIDNEY; KIDNEY DISEASES; MYOCARDIAL INFARCTION; MYOCARDIUM; RISK FACTORS; SWINE; ANGIOPLASTY, BALLOON, CORONARY;

EID: 62149097580     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.11.011     Document Type: Article

References (20)

1. Rihal C.S., Textor S.C., Grill D.E., et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105 (2002) 2259-2264
2. Mehran R., and Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 100 (2006) S11-S15
3. Mehran R., Aymong E.D., Nikolsky E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44 (2004) 1393-1399
4. Barrett B.J., and Parfey P.S. Preventing nephropathy induced by contrast medium. N Engl J Med 354 (2006) 379-386
5. Arstall M.A., Yang J., Stafford I., Betts W.H., and Horowitz J.D. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation 92 (1995) 2855-2862
6. Sochman J., Vrbska J., Musilova B., and Rocek M. Infarct Size Limitation: Acute N-acetylcysteine Defense (ISLAND trial): preliminary analysis and report after the first 30 patients. Clin Cardiol 19 (1996) 94-100
7. Tepel M., van Der G.M., Schwarzfeld C., Laufer U., Liermann D., and Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343 (2000) 180-184
8. Tepel M., Aspelin P., and Lameire N. Contrast induced nephropathy. A clinical and evidence-based approach. Circulation 113 (2006) 1799-1806
9. Marenzi G., Assanelli E., Marana I., et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354 (2006) 2773-2782
10. Andrews N.P., Prasad A., and Quyyumi A.A. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 37 (2001) 117-123
11. Vale J.A., and Proudfoot A.T. Paracetamol (acetaminophen) poisoning. Lancet 346 (1995) 547-552
12. Meyer M., Dauerman H.L., Bell S.P., Lewinter M.M., and Lustgarten D.L. Coronary venous capture of contrast during angiography. J Interv Cardiol 19 (2006) 401-404
13. Singla D.K., Lyons G.E., and Kamp T.J. Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling. Am J Physiol Heart Circ Physiol 293 (2007) H1308-H1314
14. Scharfstein J.S., Keaney J.F., Slivka A., et al. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 94 (1994) 1432-1439
15. Sochman J., Kolc J., Vrana M., and Fabian J. Cardioprotective effects of N-acetylcysteine: the reduction in the extent of infarction and occurrence of reperfusion arrhythmias in the dog. Int J Cardiol 28 (1990) 191-196
16. Singla D.K., Kaur K., Sharma A.K., Dhingra S., and Singal P.K. Probucol promotes endogenous antioxidant reserve and confers protection against reperfusion injury. Can J Physiol Pharmacol 85 (2007) 439-443
17. Briguori C., Colombo A., Violante A., et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 25 (2004) 188-189
18. Drager L.F., Andrade L., Barros de Toledo J.F., Laurindo F.R., Machado César L.A., and Seguro A.C. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 19 (2004) 1803-1807
19. de Bakker J.M., van Capelle F.J., Janse M.J., et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 77 (1988) 589-606
20. Schmidt A., Azevedo C.F., Cheng A., et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 115 (2007) 2006-2014